Karin Eastham will resign as senior vice president, CFO, treasurer, and secretary of Diversa after the company's annual shareholder meeting in mid-May, San Diego-based Diversa said today. She will continue to consult for Diversa for a period of time.
Seiichiro Tsurumaki has been appointed assistant vice president for Japan of Bruker Daltonics, a group of Bruker Biosciences, the company said on Monday. He will be responsible for marketing, sales, applications, customer support, and research activities in Japan and join Bruker's global management team. Tsurumaki joined Bruker in 2000 as sales and marketing director in Japan. Prior to that, he was a mass spectrometry sales manager at Nihon Perseptive.
Tim Yeaton has become chief scientific officer of Avaki, the Burlington, Mass.-based company said last week. He joined Avaki at the end of 2001 as chief operating officer, and was most recently its president. Before that, he was a senior vice president and general manager of server products for Macromedia. Yeaton holds an MBA from Babson College and a BS from Roger Williams University.
Michael Clegg will become professor of biological sciences at the University of California, Irvine, starting in July, the university said on Tuesday. He will direct the new Center in Evolutionary Genetics. Clegg joins UCI from the University of California, Riverside, where he is a professor of genetics in the department of botany and plant sciences.
The Pittsburgh Life Sciences Greenhouse said last week that it has promoted several of its staff members.
David Palmer has become chief operating officer, moving up from vice president of business development. Prior to joining PLSG last year, he was CEO of UK bioinformatics firm Confirmant. Palmer holds a master's degree in public management from Carnegie Mellon University and a bachelor's degree from West Virginia University.
Reed McManigle was promoted to director of investment programs and incubation services, from director of incubator and entrepreneurial services. He holds an MBA from Carnegie Mellon University, a law degree from the University of Pennsylvania, and a BA from the University of Dayton.
Pamela Bush has become investment programs manager, moving up from program associate. She holds a PhD in biological sciences from Carnegie Mellon University and a bachelor's degree in biology from Florida International University.
Nucleonics, an RNAi therapeutics firm based in Malvern, Pa., said last week that it has added the following members to its board of directors: James Barrett, general partner of NEA; Per Samuelsson, partner of HealthCap; Maxine Gowen, managing partner of S.R. One; and Robert Towarnicki, Nucleonics' president and CEO.
J. Mark Lievonen has joined the board of directors of Oncolytics, the Calgary, Canada-based company said on Monday. He is the president of Aventis Pasteur. Since 2003, he has also been a director of the Ontario Genomics Institute board. Lievonen holds an MBA and a bachelor's degree in business administration from York University.